PHGE

$0.75-0.04 (-4.99%)

Market OpenUpdated 10:21 AM EDT

BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases.

Overview Intraday ResearchPRO BacktestPRO Ask AIPRO TranscriptsPRO StatementsPRO

Intraday

Custom Range:

No data available for this range. Intraday data may be limited by the exchange.

Loading stock data…